AGILERA PHARMA AS: årsregnskap 2022 vs 2021
Slipped into loss
approved 2023-04-27; registry 2023-08-07; journal 2023 651435
Summary
What changed
Comparing Årsregnskap 2022 with 2021 for AGILERA PHARMA AS. Net result 0 NOK → -1 200 NOK. Equity 24.4k NOK → 23.2k NOK.
Pressures included: fell into a net loss; equity eroded; cash fell.
Net tougher year on the published lines.
At a glance
Scorecard
Revenue
n/m
663 NOK
—
Operating result
n/m
-1 200 NOK
—
Net result
0 NOK
-1 200 NOK
—
Equity
24.4k NOK
23.2k NOK
-4.9%
Cash
30.0k NOK
23.2k NOK
-22.6%
Total assets
30.0k NOK
23.2k NOK
-22.6%
What deteriorated
-
↓
Fell into a net loss
Net result flipped from 0 NOK profit to a loss of 1 200 NOK. Calculated
-
↓
Equity eroded
Book equity 24.4k NOK → 23.2k NOK (equity ratio 81.4% → 100.0%). Calculated
-
↓
Cash fell
Bank deposits 30.0k NOK → 23.2k NOK (-22.6% YoY). Calculated